PYC Therapeutics (ASX:PYC) Shares Ease Today: What Are Investors Watching in the Pipeline?

Sonal Goyal

06 November 2026 06:09 PM AEDT

PYC Therapeutics (ASX:PYC) Shares Ease Today: What Are Investors Watching in the Pipeline?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

PYC Therapeutics (ASX:PYC) traded at A$1.88 during the 6 November 2026 session, down 2.59%.
Its Q3 CY26 Shareholder update of 29 October 2026 said it has three investigational candidates in clinical development.
A fourth candidate is expected to enter human trials in 2027, the company said.

PYC Therapeutics (ASX:PYC) shares were quoted at A$1.88 during the 6 November 2026 trading session, down 2.59%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 29 October 2026 update. PYC is a biotechnology company developing precision medicines for genetic diseases with limited treatment options.

Latest Developments

Q3 CY26 Shareholder Update (released 29 October 2026)

PYC presented safety, tolerability and exploratory efficacy data from the single ascending dose study of PYC-003 in healthy volunteers and in participants with polycystic kidney disease, at nephrology conferences in Australia and New Zealand and in the United States. In the Phelan-McDermid syndrome program, the company progressed into investigational new drug enabling studies and presented pre-clinical data for PYC-002.

About the Company

PYC Therapeutics is an ASX-listed biotechnology company. Its update describes a pipeline built around precision medicines for genetic disease.

Business Overview

PYC's programs target genetic diseases including polycystic kidney disease and Phelan-McDermid syndrome. Its progress is reported in shareholder updates that cover clinical and pre-clinical milestones.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Early-stage biotechnology companies depend on clinical data, regulatory interactions and funding, and their shares can move on data presentations.

Risks to Watch

Early-stage programs carry clinical and regulatory risk, and the data presented so far are exploratory. Funding needs for clinical development may require future Capital raising.

Catalysts on Watch

Investors may follow further data from the PYC-003 program, the IND-enabling work on PYC-002 and the planned entry of a fourth candidate into human trials in 2027.

Final Takeaways

PYC Therapeutics (ASX:PYC) traded lower on 6 November 2026 in a session where the health care index eased. Its Q3 CY26 update of 29 October 2026 covered clinical data and pipeline progress.

FAQs

Q: What was the PYC share price on 6 November 2026?

A: PYC shares were quoted at A$1.88 during the trading session, down 2.59%.

Q: How many candidates are in clinical development?

A: Three investigational drug candidates, according to the update.

Q: What is PYC-003 studied for?

A: Polycystic kidney disease, in a single ascending dose study.

Q: When is a fourth candidate expected in human trials?

A: The company expects this in 2027.

Q: Is the session move linked to the update?

A: No. The update was released on 29 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.